TABLE 2.
Correlation of Molecular Tests With Histologic Follow-Up
| Histologic Diagnosis | ||||
|---|---|---|---|---|
| Molecular Test | Age, Range, y | Nonneoplastic | Neoplastic | Malignant |
| NRAS (n = 37) | ||||
| NRAS only (n = 20) | 17–79 | n = 12 | n = 5 (NIFTP, 2; FA, 3) | n = 3 (PTC) |
| NRAS and MIR-positive (n = 10) | 33–69 | n = 3 | n = 0 | n = 7 (PTC, 3; FTC, 3; HCC, 1) |
| NRAS and positive gene expression profile (n = 5) | 24–59 | n = 3 | n = 1 (HCA) | n = 1 (HCC) |
| NRAS and TERT promotor gene mutation (n = 1) | 66 | n = 0 | n = 0 | n = 1 (PDTC, PTC) |
| NRAS and EIF1AX mutation (n = 1) | 81 | n = 1 | n = 0 | n = 0 |
| HRAS (n = 21) | ||||
| HRAS only (n = 11) | 47–74 | n = 5 | n = 3 (NIFTP, FA, HCA) | n = 3 (PTC) |
| HRAS and MIR-positive (n = 5) | 23–56 | n = 1 | n = 3 (NIFTP, 2; FA, 1) | n = 1 (PTC) |
| HRAS and positive gene expression profile (n = 3)a | 28–52 | n = 1 | n = 0 | n = 2 (PTC)a |
| HRAS and EIF1AX (n = 2) | 35–54 | n = 2 | n = 0 | n = 0 |
| KRAS (n = 14) | ||||
| KRAS only (n = 7) | 28–71 | n = 5 | n = 1 (NIFTP) | n = 1 (FTC) |
| KRAS and MIR-positive (n = 5) | 28–49 | n = 1 | n = 2 (FA, HCA) | n = 2 (PTC) |
| KRAS and positive gene expression profile (n = 1) | 33 | n = 0 | n = 1 | n = 0 |
| KRAS and PTEN mutation (n = 1) | 61 | n = 1 | n = 0 | n = 0 |
Abbreviations: FA, follicular adenoma; FTC, follicular thyroid carcinoma; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma; MIR, miRNA classifier; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma.
a
Two had copy number alterations.